-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, with the rapid development of China's economy and the improvement of people's living standards, while China's demand for drugs continues to increase, the development of China's pharmaceutical equipment industry has also begun to show a positive development trend
.
According to data, the market size of China's pharmaceutical equipment industry has reached 21.
581 billion yuan in 2020, a year-on-year increase of 7.
26%
.
The development of the pharmaceutical equipment industry continues to improve (Source: Pharmaceutical Network) At present, under the thriving development trend of the entire industry, the development of major pharmaceutical machinery companies is also continuing to improve, and the performance of a large number of companies is increasing year by year
.
For example, although the scheduled disclosure time of Chutian Technology's 2021 annual report is April 2022, it has performed very well from the perspective of the third quarterly report
.
Specifically, the company's operating income in the first three quarters reached 3.
682 billion yuan, a year-on-year increase of 67.
24%; net profit was 401 million yuan, a year-on-year increase of 723.
53%, which has doubled the net profit of 2020
.
Among them, in the third quarter, Chutian Technology achieved revenue of 1.
291 billion yuan, a year-on-year increase of 57.
9%, and a net profit of 165 million yuan, a year-on-year increase of 413.
91%, maintaining a high growth trend
.
It is worth mentioning that although the results for 2021 have not yet been disclosed, as of now, many institutions such as Zheshang Securities, CITIC Securities, Southwest Securities, Guosen Securities and others have made 2021 profit forecasts for Chutian Technology.
Sky Technology's net profit in 2021 will be between 447.
0 million and 509.
0 million yuan, which will double from 201 million yuan in 2020
.
In addition to Chutian Technology, in fact, Tofflon, Xinhua Medical, Canaan Technology and other companies also performed very well last year
.
Tofflon disclosed in an earlier announcement that the net profit in the first three quarters of 2021 is expected to be 519 million yuan to 562 million yuan, a year-on-year increase of 80% to 95%; the net profit attributable to shareholders of listed companies is 558 million yuan, a year-on-year increase The same period increased by 93.
69%
.
On the whole, the leading companies represented by Chutian and Tofflon performed very well last year, and their net profit increased significantly
.
In this context, the industry expects that in 2022, with the rapid development of the biopharmaceutical industry, the growth of fixed asset investment in pharmaceutical companies, and the trend of import substitution, pharmaceutical equipment companies will gain more opportunities and their performance will continue to improve.
development trend
.
In addition, some people in the industry pointed out that in addition to the continuous improvement of performance, in the international market, powerful domestic pharmaceutical machine companies will also accelerate the promotion of products to overseas markets, accelerate the layout of international business, and obtain new growth points
.
It is understood that in recent years, in order to seek new growth points and expand the market development space, related companies have already turned their attention to overseas markets
.
For example, by combing through the 2021 semi-annual report of Tofflon, it can be clearly found that its performance in overseas markets is getting more and more bright
.
Specifically, in the first half of 2021, Tofflon's overseas revenue reached 448 million yuan, accounting for 24.
75% of the company's operating revenue, and the revenue growth rate in Europe increased by more than 3.
1 times year-on-year
.
And Chutian Technology has already opened its international strategic layout through the acquisition of Germany's Romaco
.
In addition, during the epidemic, downstream customers Zhifeilong Coma, Zhongsheng Group, etc.
built factories overseas, which also brought Chutian Technology an opportunity to accelerate its layout in overseas markets
.
According to data, in the first half of 2021, Chutian Technology's revenue in the Americas has increased by more than 70% year-on-year
.
Under the background that pharmaceutical machine companies are accelerating the expansion of domestic and foreign markets, and it has become the consensus of all parties to further guide the development of pharmaceutical equipment to the high-end market, the industry expects that a large number of pharmaceutical equipment companies will usher in sustained high growth in performance in the future
.
.
According to data, the market size of China's pharmaceutical equipment industry has reached 21.
581 billion yuan in 2020, a year-on-year increase of 7.
26%
.
The development of the pharmaceutical equipment industry continues to improve (Source: Pharmaceutical Network) At present, under the thriving development trend of the entire industry, the development of major pharmaceutical machinery companies is also continuing to improve, and the performance of a large number of companies is increasing year by year
.
For example, although the scheduled disclosure time of Chutian Technology's 2021 annual report is April 2022, it has performed very well from the perspective of the third quarterly report
.
Specifically, the company's operating income in the first three quarters reached 3.
682 billion yuan, a year-on-year increase of 67.
24%; net profit was 401 million yuan, a year-on-year increase of 723.
53%, which has doubled the net profit of 2020
.
Among them, in the third quarter, Chutian Technology achieved revenue of 1.
291 billion yuan, a year-on-year increase of 57.
9%, and a net profit of 165 million yuan, a year-on-year increase of 413.
91%, maintaining a high growth trend
.
It is worth mentioning that although the results for 2021 have not yet been disclosed, as of now, many institutions such as Zheshang Securities, CITIC Securities, Southwest Securities, Guosen Securities and others have made 2021 profit forecasts for Chutian Technology.
Sky Technology's net profit in 2021 will be between 447.
0 million and 509.
0 million yuan, which will double from 201 million yuan in 2020
.
In addition to Chutian Technology, in fact, Tofflon, Xinhua Medical, Canaan Technology and other companies also performed very well last year
.
Tofflon disclosed in an earlier announcement that the net profit in the first three quarters of 2021 is expected to be 519 million yuan to 562 million yuan, a year-on-year increase of 80% to 95%; the net profit attributable to shareholders of listed companies is 558 million yuan, a year-on-year increase The same period increased by 93.
69%
.
On the whole, the leading companies represented by Chutian and Tofflon performed very well last year, and their net profit increased significantly
.
In this context, the industry expects that in 2022, with the rapid development of the biopharmaceutical industry, the growth of fixed asset investment in pharmaceutical companies, and the trend of import substitution, pharmaceutical equipment companies will gain more opportunities and their performance will continue to improve.
development trend
.
In addition, some people in the industry pointed out that in addition to the continuous improvement of performance, in the international market, powerful domestic pharmaceutical machine companies will also accelerate the promotion of products to overseas markets, accelerate the layout of international business, and obtain new growth points
.
It is understood that in recent years, in order to seek new growth points and expand the market development space, related companies have already turned their attention to overseas markets
.
For example, by combing through the 2021 semi-annual report of Tofflon, it can be clearly found that its performance in overseas markets is getting more and more bright
.
Specifically, in the first half of 2021, Tofflon's overseas revenue reached 448 million yuan, accounting for 24.
75% of the company's operating revenue, and the revenue growth rate in Europe increased by more than 3.
1 times year-on-year
.
And Chutian Technology has already opened its international strategic layout through the acquisition of Germany's Romaco
.
In addition, during the epidemic, downstream customers Zhifeilong Coma, Zhongsheng Group, etc.
built factories overseas, which also brought Chutian Technology an opportunity to accelerate its layout in overseas markets
.
According to data, in the first half of 2021, Chutian Technology's revenue in the Americas has increased by more than 70% year-on-year
.
Under the background that pharmaceutical machine companies are accelerating the expansion of domestic and foreign markets, and it has become the consensus of all parties to further guide the development of pharmaceutical equipment to the high-end market, the industry expects that a large number of pharmaceutical equipment companies will usher in sustained high growth in performance in the future
.
